Clinical Trial Update: A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies [Phase 1]

View source ↗

Summary

Phase 1 trial updates for MLN2480 in combination with various agents in adults with advanced nonhematologic malignancies; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonhematologic Malignancies

Drugs mentioned

• Alisertib (alisertib)
• Cetuximab (cetuximab)
• Irinotecan (Irinotecan)
• MLN0128 (sapanisertib)
• MLN2480 (MLN2480)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Advanced Nonhematologic Malignancies | Phase 1 | Status: COMPLETED | Results posted: 2020-02-25